ENHO and metabolic dysfunction-associated steatotic liver disease: An increase in irisin levels associated with a 1.006-fold increase in protection against progression to a higher NAFLD stage (from Group 3 to Group 4, in increasing severity), while adropin was found to be 1.007 times more protective.